BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below. Some articles will have been accepted based in part or entirely on reviews undertaken for other BMJ Group journals. These will be reproduced where possible.
1) The authors should include additional data regarding underlying disease status and extra-articular manifestations of RA--including the presence of erosions, nodules, and mean titers of RF as well as anti-CCP antibodies. Some measure of average articular disease activity would also be helpful, even if articular disease activity was deemed to be minimal at the time of AE or last assessment (in the non-AE group). See #3 for relevance of this issue.
2) In addition to methotrexate usage at the time of last assessment/AE, the authors should report the number of patients "ever" using methotrexate in both groups as well as the cumulative dose of methotrexate in individual patients. Simply reporting the number of patients using methotrexate at the time of last assessment could be misleading in terms of risk attribution.
3) Related to points 1-2, the authors should determine whether the use of methotrexate is actually correlated with other disease variables such as mean articular disease severity/activity or the presence of erosions, as the association between methotrexate use and AE could reflect disparities in articular disease activity that are independently associated with the risk of AE.
4) The authors should broaden their statistical analysis of HRCT pattern and risk of AE. For example, beyond the hazard ratio of a UIP HRCT pattern (for AE), what is the negative predictive value for AE of a non-UIP pattern? This question is particularly relevant given the poor negative predictive value of a non-UIP HRCT pattern in the subset of patients who also underwent lung biopsy (reflecting marginal sensitivity).
5) Can the authors speculate regarding the limited negative predictive value of a non-UIP HRCT pattern for non-UIP histology (in the context of other studies showing much stronger correlation between HRCT pattern and histopathological findings)? 6) Can the authors specify how many of the patients with histopathological evidence of UIP occurring in the absence of a UIP HRCT pattern develop AE? If some of these discordant cases develop AE, this analysis could provide the rationale for obtaining lung biopsies in patients who do not have classic HRCT findings of UIP.
Minor Points:
7) The numbers at the bottom of Table 1 do not add up (within the subcategories of death by respiratory, non-respiratory causes). 8) In the Discussion section, the authors should break up their analysis of methotrexate's relationship to AE risk into several discrete paragraphs. 
REVIEWER

REPORTING & ETHICS
STROBE checklist should be used. In particular it would be helpful to include a flowchart showing patient identification
GENERAL COMMENTS
Summary: This study examines the incidence of acute exacerbation (AE) of in patients with rheumatoid arthritis and interstitial lung disease (RA-ILD. The study is retrospective in design and based on a small number of observations of AE in a sample of only 51 individuals with RA-ILD. As well as the retrospective design there are a number of issues that limit this study -including use of univariate analysis only and measure of disease severity. Nevertheless, it is novel being the first to consider AE of RA-ILD so does merit publication, but may only be of interest to a restricted audience.
It is important to note that I am not a clinician. While I have authored manuscripts examining the incidents of co-existing conditions in RA, including RA-ILD, my knowledge of clinical aspects is minimal. My comments mainly pertain to the design, analysis and reporting of the study Specific points: 1. page 4, line 26: The study is described a retrospective cohort study. Since the analysis compares those with RA-ILD experiencing acute exacerbation to those not, it is more accurate to describe the study as a retrospective case-control study. 2. page 7, line 47: ILD is stated as the most common extra-articular manifestation of RA. Of the references cited only one study (Turesson et al, 2003 ) explicitly examines incidence rates across multiple extra-articular conditions. RA-ILD was found to be only the 4th most common. Similarly, my own recent paper on the topic based on the UK based ERAS cohort found RA-ILD to be only the 6th most incident extra-articular manifestation (Norton et al, 2013). Another important study describing incidence of RA-ILD not cited here is by Wolfe et al (2007) . I understand that these studies may miss less severe cases of RA-ILD but, nevertheless, the statement in the text is not supported by the literature. 3. page 7, line 47: A further important point to note is that it is important to differentiate between prevalence and incidence. The studies I mention above examine incidence, whereas several other studies cited by the authors describe prevalence only. Expanding on the discussion of the prevalence/incidence of RA-ILD in the introduction is needed. This would help to explain the rather broad 1-58% prevalence rates described. 4. page 8 to 10: Since this is a retrospective study there is a risk of selection bias. The case definition is described in great detail and at time is hard to follow. 
VERSION 1 -AUTHOR RESPONSE
Response to Reviewer 1: Dr. Bernadette R. Gochuico Thank you for extremely useful comments. We tried to revise this manuscript.
1. In the Abstract, the authors conclude that acute exacerbation "has a serious impact on their survival." In the Strengths and Limitations, the authors similarly state that "acute exacerbation may have a serious impact on the survival of patients with RA-ILD as well as that of IPF." The conclusion would be clearer if the manuscript states that acute exacerbation in patients with RA-ILD is associated with a poor prognosis. In addition, IPF was not studied, and the statement about IPF should be deleted. Furthermore, the statements about carefully observing these patients are not informative and should be deleted. Patients should be carefully observed by their clinicians regardless of the presence or absence of these risk factors.
Thank you for your suggestion. We have corrected the conclusion, and deleted the statement about IPF and carefully observing the patients with these risk factors in the Strengths and Limitations, and the Abstract.
2. In the Discussion (end of 3rd paragraph), the authors state that "therefore, we think that MTX treatment should be avoided in RA patients with ILD." Given the limitations of this small retrospective single center analysis, it seems improper to include this statement in this manuscript, and it should be deleted.
Thank you for pointing out. We agree with reviewer 1, and have deleted the statement that "therefore, we think that MTX treatment should be avoided in RA patients with ILD."
3. The conclusion at the end of the Discussion should be revised to delete the last two statements (see comment 1). The authors should consider adding a final statement that larger prospective studies investigating acute exacerbations in RA-ILD are indicated.
Thank you for your suggestion. We have deleted the last two statements and added a final statement as suggested by the Reviewer.
Response to Reviewer 2: Dr. Dana Ascherman Thank you for extremely helpful comments. We tried to revise this manuscript.
Thank you for your suggestion. There were no statistically significant differences between AE and non-AE group in articular disease activity (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE occurrence (AE group). We have added the description and data regarding articular disease activity in patient characteristics of RESULTS and table 1, and the description regarding extraarticular manifestations in patient characteristics of RESULTS.
Thank you for your suggestion.
No patients had received MTX before in AE group while 2 in non-AE group. Thus, there were 6 (55%) patients who had experienced MTX treatment during observation period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE group and 802mg (32-2496) in 6 patients among non-AE group. No significant difference was observed between two groups in cumulative MTX dose (P=0.20).
In Treatment for RA of RESULTS, We have added the description regarding the number of patients "ever" using methotrexate in both groups as well as the cumulative dose of methotrexate in individual patients.
Thank you for your suggestion. We have added the description regarding the association between MTX and articular disease activity in Treatment for RA of RESULTS. In this subheading, we have shown that there were no statistically significant differences in articular disease activities between patients who had received MTX treatment and those who had not. It means that patients who had received MTX did not necessarily have more severe articular diseases than those who did not. As we answered in Point 1 above, there were no statistically significant differences between AE and non-AE group in articular disease activity. Thus, we think that articular disease activities are not related to AE occurrence in RA-ILD.
Thank you for your suggestion. When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively. It mean that when HRCT pattern was identified as a non UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 13.5% and 57.1%, respectively. We have added these results in table1 and subheading "HRCT pattern" of RESULTS. Of 5 patients with histopathological evidence of UIP in the absence of a UIP HRCT pattern, 2 develop AE. Related to Points 4-6, surgical lung biopsy may have to be considered for RA-ILD patients with non-UIP pattern on HRCT because it may demonstrate pathological UIP and we may be able to predict AE occurrence. We have added the statement regarding this into the third limitation of DISCUSSION.
7) The numbers at the bottom of Table 1 do not add up (within the subcategories of death by respiratory, non-respiratory causes).
We have deleted the numbers in Table 1 as suggested by the Reviewer and corrected "In the non-AE group, 5 of 40 patients (13%) died." into "In the non-AE group, 2 of 40 patients (5%) died of respiratory failure." in patient characteristics of RESULTS.
8) In the Discussion section, the authors should break up their analysis of methotrexate's relationship to AE risk into several discrete paragraphs.
Thank you for your suggestion. We have broken up it into two paragraphs.
Response to Reviewer 3: Dr. Sam Norton Thank you for your precious suggestions. We tried to revise this manuscript.
1. page 4, line 26: The study is described a retrospective cohort study. Since the analysis compares those with RA-ILD experiencing acute exacerbation to those not, it is more accurate to describe the study as a retrospective case-control study.
Thank you for your suggestion. As suggested by the Reviewer, we have changed "a retrospective cohort study" to "a retrospective case-control study".
2. page 7, line 47: ILD is stated as the most common extra-articular manifestation of RA. Of the references cited only one study (Turesson et al, 2003) explicitly examines incidence rates across multiple extra-articular conditions. RA-ILD was found to be only the 4th most common. Similarly, my own recent paper on the topic based on the UK based ERAS cohort found RA-ILD to be only the 6th most incident extra-articular manifestation (Norton et al, 2013). Another important study describing incidence of RA-ILD not cited here is by Wolfe et al (2007) . I understand that these studies may miss less severe cases of RA-ILD but, nevertheless, the statement in the text is not supported by the literature.
Thank you for kindly pointing out our mistake. We have corrected "ILD is the most common extraarticular manifestations" into "ILD is one of common extra-articular manifestations".
3. page 7, line 47: A further important point to note is that it is important to differentiate between prevalence and incidence. The studies I mention above examine incidence, whereas several other studies cited by the authors describe prevalence only. Expanding on the discussion of the prevalence/incidence of RA-ILD in the introduction is needed. This would help to explain the rather broad 1-58% prevalence rates described.
Thank you for kindly pointing out important issue. In previous reports, the prevalence of RA-ILD were based on different detection and diagnostic method (chest radiograph, HRCT, pulmonary function test, bronchoscopic examination, or their combination), or the selected population (symptomatic or asymptomatic series). We have corrected some references according to differentiation between prevalence and incidence and we have added "The reported prevalence is variable (1%-58%) and depends on the detection and diagnostic method, or the selected population".
4. page 8 to 10: Since this is a retrospective study there is a risk of selection bias. The case definition is described in great detail and at time is hard to follow. It would be helpful to, in accordance with the STROBE guidelines (Vandenbroucke et al, 2007), include a flow chart describing the total number of patients considered and the numbers excluded/included at each step.
Thank you for your suggestion. As suggested by reviewer and STROBE guideline, we have added the description (in patients characteristics) and flow chart (as "new" Figure 1 ) regarding inclusion and exclusion.
5. page 12, line 41: The two sentences regarding agreement on page 12 would be better moved to the description of review of HRCT images (p11, line 21).
Thank you for your suggestion. We have moved the two sentences regarding agreement on page 12 to the description of review of HRCT images.
6. page 12 , line 52: please indicate when observations were censored. e.g. on a specific date or at their last recorded visit to clinic.
Thank you for your suggestion. We had defined observation period and AE free period in the description of subheading "Data collection". We have added "according to observation period" and "according to AE free period" regarding survival and cumulative AE incidence in the description of subheading "Statistical analysis" ). This should be noted and reasons for such a short period considered in the discussion.
Thank you for pointing out an important issue. As reviewer suggested, in our study, the average time between age at onset of RA and that of RA-ILD was relatively shorter than some previous reports. However, Gabbay et al [11] reported that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In another point of view, since the current authors' institution is regional referral center for interstitial lung disease, referral bias might have increased the proportion of patients with early-stage ILD, leading above results. We have added the description in the DISCUSSION. 8. page 14, line 38: no rationale for the examination of correlations between histopathology and HRCT is presented.
Thank you for kindly pointing out our mistake. "correlation between histopathology and HRCT" was incorrect description, and thus we have corrected into "diagnostic accuracy of HRCT pattern for histopathological pattern".
9. Page 15, line 12: It is unclear why the treatment is important as no rationale is presented in the introduction. Use of MTX was higher in the AE group but this could be due to confounding (e.g. MTX use increased in more severe RA)
Thank you for pointing out an important issue. Reviewer 2 also pointed out it. We have added the description regarding the association between MTX and articular disease activity in Treatment for RA of RESULTS. In this subheading, we have shown that there were no statistically significant differences in articular disease activities between patients who received MTX treatment and those who did not. It means that patients who had received MTX did not necessarily have more severe articular diseases than those who did not. As we showed in "new" table 1, there were no statistically significant differences between AE and non-AE group in articular disease activity. Thus, we think that articular disease activities are not related to AE occurrence in RA-ILD.
10. page 15, line 38: One year cumulative incidence is reported in the text. It would be useful to also report cumulative incidence at a later point in the text (e.g. 10 years). Confidence intervals must be presented. It would also be useful to report the total-number of person years.
As suggested by reviewer, we have added 5 years cumulative incidence and 95%CI. In our study, 1-year AE incidence was based on person year method. Please see the description of subheading "statistical analysis". We think the term "1-year AE incidence (%)" is easier to be understood than the term "incidence rate (persons-years)" for clinician. We have added "1-year AE incidence was based on person year method" in the description of statistical analysis. 12. page 17, line 14 to 56: When discussing AE incidence reported by previous studies it is important to note that precision of these estimates (i.e. width of confidence intervals). The authors cannot "AE occurs les frequently in RA-ILD than IPF" when when confidence intervals are likely to include the rate observed in IPF.
Thank you for pointing out an important issue. We did not directly compare AE incidence between RA-ILD and IPF. Thus, we have deleted the description regarding comparison between RA-ILD and IPF.
13. page 18, line 8 to page 19, line 30: An extensive discussion of the association between MTX and AE in RA-ILD is provided. This was not a main aim of the study (if it is it should be outline in the discussion). I understand that some discussion of the potential link between MTX and RA-ILD and AE may be important. However, it is an over interpretation of the strength of the findings of the study to state that "MTX treatment should be avoided in RA patients with ILD."
Thank you for your suggestion. According to the suggestion by the Reviewer, we have deleted the statement that "therefore, we think that MTX treatment should be avoided in RA patients with ILD."
14. page 20, line 20: to the limitations the authors should add the small sample size leading to low power and imprecision of the estimated incidence rates and no measure of RA disease severity.
2. The risk attribution for AE may be overstated (in part because of the relatively small cohort size). In short, the authors should probably temper their conclusions by stating that older age, UIP pattern on HRCT, and methotrexate usage are "associated with" the development of AE.
-Thank you for your suggestion. We have tempered the conclusion, as a reviewer suggested.
1) In the abstract and throughout the text, the authors refer to older age, HRCT evidence of UIP, and methotrexate usage as "risk factors" for AE. However, attributing risk in such a small study is questionable, particularly without multivariate analysis (see comment 2). The authors should consider tempering their conclusions by stating that these variables are "associated with the development of AE in this cohort."
-Thank you for your suggestion. Another reviewer also suggested it. We have tempered the conclusions and descriptions regarding risk factors, as a reviewer suggested.
2) Although this analysis does not identify differences in extra-articular disease manifestations or smoking history that might distinguish RA-ILD patients with/without AE, there is certainly a suggestion that such differences could exist and be statistically significant in a larger study (e.g., 27% vs. 13% extra-articular disease manifestations beyond ILD, 82% vs. 55% current/ever smokers). The authors should include these considerations in the Discussion section.
-Thank you for your suggestion. We have included the consideration in the second limitation of discussion section. "In our analysis, the incidence of extra-articular manifestations beyond ILD and the proportion of current/former smokers in AE group were higher than those in non-AE group (27% vs. 13% and 82% vs. 55%, respectively), with no statistically significant differences. Such differences might be statistically significant in a larger study. Therefore, larger studies are necessary to confirm our results."
3) If possible, the authors should include some measure of average disease activity (i.e., average DAS28-CRP) during the observation period, as this variable could highlight differences in articular disease activity between subgroups that is not captured by one-time measurements at study endpoints.
-In our first revision, we had added data regarding articular disease activity at the last visit or at the AE occurrence. Because these were recent data, we could provide them in all patients. However, we could not obtain earlier data (before referral to our hospital) in any of patients. Furthermore, disease activity scores during the observation period were missing in some of the patients. Thus, unfortunately, we could not provide average disease activity during the observation period. But, we hope we will study the association between average articular disease activity and pulmonary disease activity in the near future. We have defined chronic ILD in Subjects of MATERIALS AND METHODS. "Chronic ILD was defined as the ILD which had been stable for over 3 months."
5) The reporting of methotrexate usage remains somewhat confusing (page 16, line 38). Do the authors mean that 2 patients in the non-AE group received methotrexate during the study period, but then discontinued this medication prior to the study endpoint?
-Yes, we do. As a reviewer pointed out, it was confusing description. Thus, we have corrected it. 6) On page 14, line 47, the authors should clarify whether the statistically significant differences in mortality between the AE and non-AE groups refers specifically to pulmonary vs. overall mortality.
-Thank you for your kindly pointing out. In this context, "the statistically significant differences" refers to death caused by respiratory failure (pulmonary mortality). We have corrected it.
7) In Figure 3 , the Kaplan-Meier plot does not appear to match the statistics reported in the text. For example, if 7/11 patients with AE died, the cumulative endpoint for this subgroup should be 36%. Similarly, the cumulative survival for the combined cohort should be 39/51=76%.
-In figure 3 and figure 4 , we showed the survival according to HRCT pattern subgroup and that of AE group and non-AE group, respectively. I supposed that a reviewer may have a question for figure 4, but not figure 3. A reviewer depicted the direct method based on the simple calculation that is made of the percentage of patients alive or dead at endpoint among population. But, Kaplan-Meier method is based on the calculation that is made of the probabilities of survival. The survival probabilities are calculated using not only population and event (e.g. death) but time interval and censoring. For each time interval we estimate the probability that patients who have survived to the beginning will survive to the end. This is a conditional probability (the probability of being a survivor at the end of the interval on condition that the subject was a survivor at the beginning of the interval). Survival to any time point is calculated as the product of the conditional probabilities of surviving each time interval. (Bland et al. BMJ 1998; 317: 1572.) Thus, the survival (%) at endpoint from Kaplan-Meier method is different from that from direct method. Figure 3 and figure 4 match the result reported in text. Table 1 , the mortality rates within each subgroup do not equate with the numbers listed for the combined cohort (should be 9 pulmonary, 3 non-pulmonary deaths overall).
8) In
-Thank you for your kindly pointing out our mistake. We have corrected it.
